A Phase Ⅲ, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Ensartinib Versus Placebo as Adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Stage IB- IIIB Non-small Cell Lung Cancer.
Overview
- Phase
- Phase 3
- Intervention
- Ensartinib
- Conditions
- Non-small Cell Lung Cancer
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Enrollment
- 202
- Locations
- 1
- Primary Endpoint
- Disease free survival (DFS)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.
Detailed Description
This is a double-blind, randomized, placebo-controlled, multicenter, Phase III study, the primary endpoint is disease-free survival. Participants in the experimental arm will receive Ensatinib at 225 mg orally once a day taken with or without food for 2 years. Participants in the control arm will receive placebo at 225 mg orally once a day taken with or without food for 2 years. Treatments will continue until disease recurrence, meeting one of treatment discontinuation criteria (eg, patient decision, adverse event, pregnancy), or achieving a maximum treatment duration of 2 years, whichever occurs earlier. At the time of treatment discontinuation, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung.
- •Patients must be classified post-operatively as Stage IB-IIIB(T3N2M0) on the basis of pathologic criteria after complete surgical resection(R0).
- •Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
- •Confirmation by the central laboratory that the tumour harbours ALK positive.
- •At least 1-year life expectancy.
- •Eastern Cooperative Group (ECOG) Performance Status score of 0 or
- •The laboratory test values should meet the following requirements:
- •Absolute neutrophil count ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L ，hemoglobin ≥9g/dL
- •Total bilirubin≤ 1.5 x institutional upper limit of normal,AST and ALT≤ 2.5 x institutional upper limit of normal
- •Creatinine≤ 1.5 x institutional upper limit of normal ,if not, Creatinine Clearance ≥ 50 ml/min
Exclusion Criteria
- •Patients who are participating in other clinical studies or are receiving other investigational drugs , or investigational devices within 4 weeks before the first dose of our study drugs. If patients are participating in non-interventional clinical trials, they can be included in this study.
- •Patients who have a presence of unresectable or metastatic disease, the pathological diagnosis show the microscopically positive surgical margins or extranodal invasion, or residual disease of surgery，or had only segmentectomies or wedge resections.
- •Patients with superior sulcus cancer.
- •Patients who have received a surgery with total right lung resection.
- •History of other malignancies within 5 years of the first dose of the study drug, except: malignant tumors that can be expected to recover after treatment.
- •Prior treatment with other anti-cancer treatments or NSCLC including chemotherapy, radiotherapy, targeted therapy (such as small molecule tyrosine kinase inhibitors targeting EGFR, VEGFR or other pathways, monoclonal antibodies, etc.), immunotherapy, investigational therapy, etc. but except platinum based chemotherapy for adjuvant therapy.
- •Major surgery within 3 weeks of the first dose of the study drug.
- •Patients who have used traditional Chinese medicines and traditional Chinese medicine preparations with indications for anti-tumor therapy or adjuvant therapy for tumors within 14 days of the first dose of the study drug.
- •Patients who have used the following drugs within 14 days before the first dose : strong inhibitors, strong inducers of CYP3A or CYP3A substrates with a narrow therapeutic index.
- •Patients who have severe cardiovascular disease.
Arms & Interventions
Ensatinib
Ensatinib ( 225 mg, once daily), in accordance with the randomization schedule
Intervention: Ensartinib
Placebo
Placebo ( 225 mg, once daily), in accordance with the randomization schedule
Intervention: Placebo
Outcomes
Primary Outcomes
Disease free survival (DFS)
Time Frame: up to 5 years
From date of randomization until date of tumor recurrence or death, whichever occurs earlier
Secondary Outcomes
- DFS rate at 3 years(Assessed at 3 years)
- DFS rate at 5 years(Assessed at 5 years)
- Overall survival (OS)(Assessed at 5 years)
- OS rate at 5 years(up to 5 years)